EMA recommends updating Wegovy label for obesity-related HFpEF based on STEP HFpEF trials.

The European Medicines Agency (EMA) has recommended updating the label for Novo Nordisk's Wegovy® (semaglutide 2.4 mg) to include its benefits for obesity-related heart failure with preserved ejection fraction (HFpEF). This recommendation is based on STEP HFpEF trials, demonstrating improved heart failure symptoms and physical function in patients. Wegovy is already approved for weight management and has shown additional health benefits in heart health.